Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Labcorp Drug Development.

    Client Virtual Booth

    LABCORP DRUG DEVELOPMENT

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    SERVICES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Labcorp Drug Development
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    Burlington, North Carolina 27215
    Telephone
    Telephone
    +1.888.268.2623
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://drugdevelopment.labcorp.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/labcorpdrugdev/
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    left grey arrow
    right gray arrow
    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Enterome Completes Patient Enrollment Of Phase 2 ROSALIE Study Evaluating Its Lead Immunotherapy, EO2401, In Recurrent Glioblastoma

    Details:

    EO2401, in combination with an immune checkpoint inhibitor (nivolumab) +/- an anti-VEGF therapy (bevacizumab) in patients with first progression/recurrence of glioblastoma, an aggressive form of brain cancer.


    Lead Product(s): EO2401,Nivolumab,Bevacizumab

    Therapeutic Area: Oncology Product Name: EO2401

    Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine

    Recipient: Enterome

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable December 12, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    HiberCell Initiates its Phase 1a/b Clinical Trial of HC-7366 in Patients with Advanced Solid Tumors

    Details:

    The first-in-human Phase 1a/b clinical trial, designed to establish maximum tolerated dose, while evaluating safety and tolerability, and to establish recommended Phase 2 dose for HC-7366, selective, orally bioavailable modulator of GNC2 in patients with advanced solid tumors.


    Lead Product(s): HC-7366-K

    Therapeutic Area: Oncology Product Name: HC-7366

    Highest Development Status: Phase IProduct Type: Small molecule

    Recipient: HiberCell

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable February 24, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    HiberCell Initiates Phase 1a Clinical Trial of HC-5404-FU, an ER Stress Modulator

    Details:

    The primary endpoints are to establish HC-5404-FU’s Maximum Tolerated Dose (MTD) and to monitor its safety and tolerability in patients with selected, advanced solid tumors.


    Lead Product(s): HC-5404

    Therapeutic Area: Oncology Product Name: HC-5404-FU

    Highest Development Status: Phase IProduct Type: Small molecule

    Recipient: HiberCell

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable June 10, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    WellmarkerBio Receives Approval for Phase I Clinical Trial from the Australian Therapeutic Goods Administration

    Details:

    Wellmarker has received approval from the Australian Therapeutic Goods Administration (TGA) for a Phase I clinical trial using WM-S1-030, a targeted anti-cancer drug for colorectal cancer and progressive cancer.


    Lead Product(s): WM-S1-030

    Therapeutic Area: Oncology Product Name: WM-S1-030

    Highest Development Status: Phase IProduct Type: Small molecule

    Recipient: Wellmarker Bio

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable March 03, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    KBP Biosciences Announces Data Presentation at the American Society of Nephrology Annual Meeting

    Details:

    The upcoming data to be presented at the American Society of Nephrology (ASN) Annual Meeting showcases a pre-clinical study investigating the effect of KBP-5074 on aldosterone-mediated renal injury in the uninephrectomized SD rat CKD model.


    Lead Product(s): KBP-5074

    Therapeutic Area: Nephrology Product Name: KBP-5074

    Highest Development Status: Phase IIProduct Type: Small molecule

    Recipient: KBP Biosciences

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable October 22, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    KBP Biosciences Announces Publication of Trial Design Manuscript for Ongoing BLOCK CKD Phase 2b Study of KBP-5074

    Details:

    BLOCK-CKD is a Phase 2b, international, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of KBP-5074, on top of current therapy, in patients with Stage 3B/4 CKD and uncontrolled hypertension.


    Lead Product(s): KBP-5074

    Therapeutic Area: Nephrology Product Name: KBP-5074

    Highest Development Status: Phase IIProduct Type: Small molecule

    Recipient: KBP Biosciences

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable June 29, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    KBP Biosciences’ KBP-5074 Appears Well Tolerated in a single dose PK Study in severe CKD patients with and without hemodialysis

    Details:

    Single doses of 0.5 mg KBP-5074 were generally well tolerated in patients with severe CKD, with or without hemodialysis . Overall drug exposure was significantly lower in hemodialyzed patients vs. non-hemodialyzed patients.


    Lead Product(s): KBP-5074

    Therapeutic Area: Nephrology Product Name: Undisclosed

    Highest Development Status: Phase IIProduct Type: Small molecule

    Recipient: KBP Biosciences

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable May 21, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    KBP Biosciences Completes Enrollment of BLOCK CKD Phase 2b Study of KBP-5074

    Details:

    BLOCK CKD is a randomized, double-blind, placebo-controlled, multi-center study to assess the efficacy, safety, and pharmacokinetics of KBP-5074 in patients with moderate-to-severe CKD and uncontrolled hypertension.


    Lead Product(s): KBP-5074

    Therapeutic Area: Nephrology Product Name: Undisclosed

    Highest Development Status: Phase IIProduct Type: Small molecule

    Recipient: KBP Biosciences

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable May 20, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search